Amgen Inc (AMGN) 176.44 $AMGN
Third Point buys stake in Baxter, wants to help pick new CEO
AP - Wed Aug 05, 3:37PM CDT
NEW YORK (AP) — Hedge fund Third Point has become the biggest shareholder in Baxter International and wants to help choose the medical products maker's next CEO.
AGN: 336.64 (+5.64), BAX: 42.13 (+1.82), AMGN: 176.44 (+1.64), DOW: 47.13 (+0.44)
What Company Will Be Fastest Growing Big-Cap Biotech?
at Investor's Business Daily - Wed Aug 05, 1:58PM CDT
While drugs for treating and curing hepatitis C have made one biotech company the envy of the industry, another biotech -- Celgene -- is poised to break ahead of its peer pack over the next few years. Celgene's (CELG) sales and profit growth is seen...
AGN: 336.64 (+5.64), BIIB: 335.41 (+5.03), GEVA: 238.60 (+2.80), PCYC: 261.25 (+1.70), GILD: 118.66 (-0.21), AZN: 34.54 (+0.20), ALXN: 197.94 (+0.79), RCPT: 228.97 (+0.97), AMGN: 176.44 (+1.64), ABBV: 70.30 (+0.35), JUNO: 46.67 (+0.17), CELG: 132.72 (+1.64)
Sustained Release Ocular Drug Delivery Systems, 2015 - 2025
M2 - Wed Aug 05, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2gzr3/sustained_release) has announced the addition of the "Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)" report to their offering. The Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)' report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases. The report covers various aspects such as technological progress, product pipeline, target indications, industry and academic research programs to assess new evolving opportunities. We have provided a competitive spider web analysis to compare different implants based on technical parameters (drug elution rate, amount of drug delivered, life of implant etc.) and their likely user friendliness. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry. The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 - 2020 and 2020 - 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systemsbased on the current expected launch timelines, adoption rates and the estimated end-use price points.The figures mentioned in this report are in USD, unless otherwise specified. Highlights: - More than 25 companies are currently working on developing sustained release drug delivery systems for the treatment of ocular indications. Examples of some key players include pSivida, Allergan, Ocular Therapeutix, Neurotech Pharmaceuticals, Icon BioScience and GrayBug. - Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien. - Majority of the systems (52%) are in preclinical stage of development. Over 10 systems are currently undergoing late stage clinical trial studies. Once approved, these inserts are likely to provide a major impetus to the overall market. - DME and Uveitis will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. In the mid to long term, the growth will be fostered by launch of sustained release systems for glaucoma and AMD. In fact, more than 15 sustained release formulations are under development for the treatment of glaucoma. - Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of this market. During our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts. - The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Product Profiles and Sales Forecast 6. Company Profiles 7. Venture Capital Support 8. Recent Partnerships 9. SWOT Analysis 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List Of Companies Companies Mentioned - Partial List of Companies - 3i Plc - AbbVie - Abell Foundation - Aciont, Inc. - Actavis Plc - Aerie Pharmaceutical - Ain Shams University, Cairo, Egypt - Alcon - Alimera Sciences - Allergan - Alliance Medical Products Inc - Alpha Associates - Amgen Inc. - Amorphex Therapeutics - Apax Partners - Ascension Health Ventures - Atlas Venture - Auritec Pharmaceuticals - Avida Group - Bausch & Lomb - Baxter Venture - Bayer Healthcare - BCN Peptides - Ben Venue Laboratories - BioLight Israeli Life Sciences Investments Ltd. - Brandon Biosciences - Brecon Pharmaceuticals Ltd - Brown Advisory For more information visit http://www.researchandmarkets.com/research/g2...ed_release
AGN: 336.64 (+5.64), ALIM: 4.69 (-0.10), AMGN: 176.44 (+1.64), OCUL: 23.43 (+1.38)
Biotech Stock Roundup: Baxalta Rejects Shire Bid, Amgen's Beat & Raise Quarter - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 05, 9:44AM CDT
In the midst of earnings, acquisitions continue to make news with the latest being Shire's proposal for Baxalta (BXLT).
VRTX: 141.22 (+0.92), LXRX: 12.90 (+0.23), VVUS: 1.30 (unch), AMGN: 176.44 (+1.64), BXLT: 37.30 (+0.20), REGN: 592.40 (+11.46), CELG: 132.72 (+1.64)
Biocept Launches its First Liquid Biopsy Diagnostic Test for Colorectal Cancer
Business Wire - Wed Aug 05, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced the launch of its proprietary quantitative Target Selector(TM) assay targeting KRAS mutations utilizing a patient's blood sample. Testing for this predictive biomarker will help physicians identify patients who might benefit from targeted therapies currently available to treat solid tumor cancers. In addition, the high sensitivity of Biocept's Target Selector(TM) allows the test to be used for monitoring patients for response to treatment and progression of disease during the course of therapy.
AMGN: 176.44 (+1.64), BIOC: 2.40 (+0.03)
Mixed Biotech Earnings put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Aug 04, 5:00AM CDT
The biotech sector as a whole has been a mixed performer this earnings season. Let's take a look at how biotech ETFs are responding?
BIIB: 335.41 (+5.03), GILD: 118.66 (-0.21), ALXN: 197.94 (+0.79), IBB: 386.72 (+2.91), BBH: 141.62 (+1.00), AMGN: 176.44 (+1.64), CELG: 132.72 (+1.64)
Will Ligand Pharmaceuticals (LGND) Beat Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 03, 3:00PM CDT
Ligand Pharmaceuticals LGND), which is scheduled to report second-quarter results on Aug 4, had recorded a positive earnings surprise of 66.67% last quarter.
LGND: 111.25 (+1.94), AMGN: 176.44 (+1.64), AGIO: 111.85 (+0.73), VKTX: 6.10 (+0.20)
Company News for August 03, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Aug 03, 9:10AM CDT
Companies in the News are: AMGN,EA,LNKD,TYC
TYC: 38.28 (+0.01), LNKD: 192.70 (-2.06), EA: 75.16 (+3.36), AMGN: 176.44 (+1.64)
Allergan is Cramer's Favorite Stock, Teva Deal Was 'Incredible'
at The Street - Sat Aug 01, 8:15AM CDT
Action Alerts PLUS Portfolio Manager Jim Cramer and Research Director Jack Mohr sat down to talk about their favorite company in the portfolio: Allergan.
AGN: 336.64 (+5.64), BIIB: 335.41 (+5.03), PFE: 35.82 (-0.29), MRK: 59.10 (+0.40), AMGN: 176.44 (+1.64), TEVA: 71.19 (+0.50)
'Fast Money' Recap: Goodbye, July; Will August Be More of the Same?
at The Street - Sat Aug 01, 4:00AM CDT
The trading panel discussed health care, biotech and energy stocks.
VLO: 64.82 (+0.39), TSO: 98.12 (+1.30), GILD: 118.66 (-0.21), XOP: 36.75 (-0.47), PFE: 35.82 (-0.29), XOM: 77.17 (unch), AMGN: 176.44 (+1.64), GDX: 13.09 (-0.20), CVX: 84.03 (-1.18), Z: 72.42 (-1.78), XLE: 67.18 (-0.51), CELG: 132.72 (+1.64)
LinkedIn and Expedia are big market movers
AP - Fri Jul 31, 3:33PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
MGI: 10.15 (-0.21), LNKD: 192.70 (-2.06), EXPE: 126.79 (+2.23), COLM: 65.97 (+1.21), AMGN: 176.44 (+1.64), HBI: 28.91 (-0.22), LYG: 5.20 (+0.02)
Oil Skidded 21% During July -- and Was a Big Drag on Stocks
at The Street - Fri Jul 31, 3:00PM CDT
July is a mixed month for markets as the S&P 500 and Nasdaq closes with slight gains, while the Dow Jones Industrial Average sees a loss.
RCL: 89.95 (+0.80), LNKD: 192.70 (-2.06), XOM: 77.17 (unch), COP: 49.12 (-0.75), AMGN: 176.44 (+1.64), BP: 35.87 (-0.67), CVX: 84.03 (-1.18), PTR: 94.40 (-0.48), XLE: 67.18 (-0.51), STO: 16.52 (+0.05)
Amgen Stock Hits High As Street Eyes Growth Drivers
at Investor's Business Daily - Fri Jul 31, 2:35PM CDT
Big biotech Amgen (AMGN) hit a new high in early trading Friday and got several price-target increases from analysts after its strong Q2 and guidance increase late Thursday. Cowen analyst Eric Schmidt raised his price target to 193 from 189 based not...
VRX: 262.52 (+2.54), PFE: 35.82 (-0.29), MRK: 59.10 (+0.40), AMGN: 176.44 (+1.64), SNY: 54.71 (+1.22), REGN: 592.40 (+11.46)
Amgen (AMGN) Stock Higher as Barclays Increases Price Target
at The Street - Fri Jul 31, 2:31PM CDT
Amgen (AMGN) price target was raised to $185 from $180 at Barclays, which maintained its 'equal weight' rating.
AMGN: 176.44 (+1.64)
Stocks Are Mixed as Crude Oil Closes Worst Month of 2015
at The Street - Fri Jul 31, 1:48PM CDT
Stocks are mixed by mid-afternoon Friday as crude oil prices fall and energy stocks sell off.
RCL: 89.95 (+0.80), LNKD: 192.70 (-2.06), EA: 75.16 (+3.36), XOM: 77.17 (unch), AMGN: 176.44 (+1.64), CVX: 84.03 (-1.18), CCE: 51.84 (+1.32)
Amgen Crushes Wall Street's Expectations in Q2, But This Figure Is a Bit Worrisome
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 31, 1:41PM CDT
Source: Amgen via Flickr. The original biotech blue-chip stock, Amgen , continued its recent string of earnings beats when it reported its second-quarter earnings results after the closing bell last night. Amgen's Q2, by the numbers For the...
AMGN: 176.44 (+1.64)
Stocks Are Slightly Higher Despite Energy Drag
at The Street - Fri Jul 31, 10:28AM CDT
Markets move slightly higher Friday shaking off earlier pressure from the energy sector
RCL: 89.95 (+0.80), LNKD: 192.70 (-2.06), EA: 75.16 (+3.36), XOM: 77.17 (unch), AMGN: 176.44 (+1.64), CVX: 84.03 (-1.18), CCE: 51.84 (+1.32)
Small-Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Fri Jul 31, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szb6j5/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celator Pharmaceuticals, Inc. - CellAct Pharma GmbH - Cerulean Pharma, Inc. - Cornerstone Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - CytRx Corporation - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - ImmunoCellular Therapeutics, Ltd. - Immunomedics, Inc. - Inbiopro Solutions Pvt. Ltd For more information visit http://www.researchandmarkets.com/research/sz...lcell_lung
IMMU: 2.06 (-0.01), CERU: 3.95 (-0.12), AMGN: 176.44 (+1.64), LLY: 84.73 (+0.68), BIND: 4.58 (-0.13), GSK: 44.17 (+0.72), BMY: 65.06 (+0.22), IMUC: 0.46 (-0.01), AZN: 34.54 (+0.20), CYTR: 2.62 (-0.04), AVEO: 1.41 (-0.03), ABBV: 70.30 (+0.35), EXEL: 6.28 (-0.34), ARRY: 6.10 (+0.29)
Stocks Open Mixed, Dow Lags; Expedia, Amgen, NewLink Rising
at Investor's Business Daily - Fri Jul 31, 9:37AM CDT
Stocks fought in tightly mixed action early Friday, with earnings news and economic data powering a large share of the action. The Nasdaq improved 0.2% and the S&P 500 rose 0.1%, while the Dow Jones industrial average struggled with a 0.1% decline....
MRK: 59.10 (+0.40), UHS: 143.96 (-2.28), PFE: 35.82 (-0.29), NLNK: 51.74 (-0.09), EXPE: 126.79 (+2.23), AMGN: 176.44 (+1.64), XOM: 77.17 (unch), CVX: 84.03 (-1.18), OUTR: 68.71 (-0.85)
Third Point buys stake in Baxter, wants to help pick new CEO
AP - Wed Aug 05, 3:37PM CDT
NEW YORK (AP) — Hedge fund Third Point has become the biggest shareholder in Baxter International and wants to help choose the medical products maker's next CEO.
AGN: 336.64 (+5.64), BAX: 42.13 (+1.82), AMGN: 176.44 (+1.64), DOW: 47.13 (+0.44)
What Company Will Be Fastest Growing Big-Cap Biotech?
at Investor's Business Daily - Wed Aug 05, 1:58PM CDT
While drugs for treating and curing hepatitis C have made one biotech company the envy of the industry, another biotech -- Celgene -- is poised to break ahead of its peer pack over the next few years. Celgene's (CELG) sales and profit growth is seen...
AGN: 336.64 (+5.64), BIIB: 335.41 (+5.03), GEVA: 238.60 (+2.80), PCYC: 261.25 (+1.70), GILD: 118.66 (-0.21), AZN: 34.54 (+0.20), ALXN: 197.94 (+0.79), RCPT: 228.97 (+0.97), AMGN: 176.44 (+1.64), ABBV: 70.30 (+0.35), JUNO: 46.67 (+0.17), CELG: 132.72 (+1.64)
Sustained Release Ocular Drug Delivery Systems, 2015 - 2025
M2 - Wed Aug 05, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2gzr3/sustained_release) has announced the addition of the "Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)" report to their offering. The Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)' report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases. The report covers various aspects such as technological progress, product pipeline, target indications, industry and academic research programs to assess new evolving opportunities. We have provided a competitive spider web analysis to compare different implants based on technical parameters (drug elution rate, amount of drug delivered, life of implant etc.) and their likely user friendliness. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry. The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 - 2020 and 2020 - 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systemsbased on the current expected launch timelines, adoption rates and the estimated end-use price points.The figures mentioned in this report are in USD, unless otherwise specified. Highlights: - More than 25 companies are currently working on developing sustained release drug delivery systems for the treatment of ocular indications. Examples of some key players include pSivida, Allergan, Ocular Therapeutix, Neurotech Pharmaceuticals, Icon BioScience and GrayBug. - Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien. - Majority of the systems (52%) are in preclinical stage of development. Over 10 systems are currently undergoing late stage clinical trial studies. Once approved, these inserts are likely to provide a major impetus to the overall market. - DME and Uveitis will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. In the mid to long term, the growth will be fostered by launch of sustained release systems for glaucoma and AMD. In fact, more than 15 sustained release formulations are under development for the treatment of glaucoma. - Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of this market. During our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts. - The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Product Profiles and Sales Forecast 6. Company Profiles 7. Venture Capital Support 8. Recent Partnerships 9. SWOT Analysis 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List Of Companies Companies Mentioned - Partial List of Companies - 3i Plc - AbbVie - Abell Foundation - Aciont, Inc. - Actavis Plc - Aerie Pharmaceutical - Ain Shams University, Cairo, Egypt - Alcon - Alimera Sciences - Allergan - Alliance Medical Products Inc - Alpha Associates - Amgen Inc. - Amorphex Therapeutics - Apax Partners - Ascension Health Ventures - Atlas Venture - Auritec Pharmaceuticals - Avida Group - Bausch & Lomb - Baxter Venture - Bayer Healthcare - BCN Peptides - Ben Venue Laboratories - BioLight Israeli Life Sciences Investments Ltd. - Brandon Biosciences - Brecon Pharmaceuticals Ltd - Brown Advisory For more information visit http://www.researchandmarkets.com/research/g2...ed_release
AGN: 336.64 (+5.64), ALIM: 4.69 (-0.10), AMGN: 176.44 (+1.64), OCUL: 23.43 (+1.38)
Biotech Stock Roundup: Baxalta Rejects Shire Bid, Amgen's Beat & Raise Quarter - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 05, 9:44AM CDT
In the midst of earnings, acquisitions continue to make news with the latest being Shire's proposal for Baxalta (BXLT).
VRTX: 141.22 (+0.92), LXRX: 12.90 (+0.23), VVUS: 1.30 (unch), AMGN: 176.44 (+1.64), BXLT: 37.30 (+0.20), REGN: 592.40 (+11.46), CELG: 132.72 (+1.64)
Biocept Launches its First Liquid Biopsy Diagnostic Test for Colorectal Cancer
Business Wire - Wed Aug 05, 6:00AM CDT
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced the launch of its proprietary quantitative Target Selector(TM) assay targeting KRAS mutations utilizing a patient's blood sample. Testing for this predictive biomarker will help physicians identify patients who might benefit from targeted therapies currently available to treat solid tumor cancers. In addition, the high sensitivity of Biocept's Target Selector(TM) allows the test to be used for monitoring patients for response to treatment and progression of disease during the course of therapy.
AMGN: 176.44 (+1.64), BIOC: 2.40 (+0.03)
Mixed Biotech Earnings put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Aug 04, 5:00AM CDT
The biotech sector as a whole has been a mixed performer this earnings season. Let's take a look at how biotech ETFs are responding?
BIIB: 335.41 (+5.03), GILD: 118.66 (-0.21), ALXN: 197.94 (+0.79), IBB: 386.72 (+2.91), BBH: 141.62 (+1.00), AMGN: 176.44 (+1.64), CELG: 132.72 (+1.64)
Will Ligand Pharmaceuticals (LGND) Beat Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 03, 3:00PM CDT
Ligand Pharmaceuticals LGND), which is scheduled to report second-quarter results on Aug 4, had recorded a positive earnings surprise of 66.67% last quarter.
LGND: 111.25 (+1.94), AMGN: 176.44 (+1.64), AGIO: 111.85 (+0.73), VKTX: 6.10 (+0.20)
Company News for August 03, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Aug 03, 9:10AM CDT
Companies in the News are: AMGN,EA,LNKD,TYC
TYC: 38.28 (+0.01), LNKD: 192.70 (-2.06), EA: 75.16 (+3.36), AMGN: 176.44 (+1.64)
Allergan is Cramer's Favorite Stock, Teva Deal Was 'Incredible'
at The Street - Sat Aug 01, 8:15AM CDT
Action Alerts PLUS Portfolio Manager Jim Cramer and Research Director Jack Mohr sat down to talk about their favorite company in the portfolio: Allergan.
AGN: 336.64 (+5.64), BIIB: 335.41 (+5.03), PFE: 35.82 (-0.29), MRK: 59.10 (+0.40), AMGN: 176.44 (+1.64), TEVA: 71.19 (+0.50)
'Fast Money' Recap: Goodbye, July; Will August Be More of the Same?
at The Street - Sat Aug 01, 4:00AM CDT
The trading panel discussed health care, biotech and energy stocks.
VLO: 64.82 (+0.39), TSO: 98.12 (+1.30), GILD: 118.66 (-0.21), XOP: 36.75 (-0.47), PFE: 35.82 (-0.29), XOM: 77.17 (unch), AMGN: 176.44 (+1.64), GDX: 13.09 (-0.20), CVX: 84.03 (-1.18), Z: 72.42 (-1.78), XLE: 67.18 (-0.51), CELG: 132.72 (+1.64)
LinkedIn and Expedia are big market movers
AP - Fri Jul 31, 3:33PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
MGI: 10.15 (-0.21), LNKD: 192.70 (-2.06), EXPE: 126.79 (+2.23), COLM: 65.97 (+1.21), AMGN: 176.44 (+1.64), HBI: 28.91 (-0.22), LYG: 5.20 (+0.02)
Oil Skidded 21% During July -- and Was a Big Drag on Stocks
at The Street - Fri Jul 31, 3:00PM CDT
July is a mixed month for markets as the S&P 500 and Nasdaq closes with slight gains, while the Dow Jones Industrial Average sees a loss.
RCL: 89.95 (+0.80), LNKD: 192.70 (-2.06), XOM: 77.17 (unch), COP: 49.12 (-0.75), AMGN: 176.44 (+1.64), BP: 35.87 (-0.67), CVX: 84.03 (-1.18), PTR: 94.40 (-0.48), XLE: 67.18 (-0.51), STO: 16.52 (+0.05)
Amgen Stock Hits High As Street Eyes Growth Drivers
at Investor's Business Daily - Fri Jul 31, 2:35PM CDT
Big biotech Amgen (AMGN) hit a new high in early trading Friday and got several price-target increases from analysts after its strong Q2 and guidance increase late Thursday. Cowen analyst Eric Schmidt raised his price target to 193 from 189 based not...
VRX: 262.52 (+2.54), PFE: 35.82 (-0.29), MRK: 59.10 (+0.40), AMGN: 176.44 (+1.64), SNY: 54.71 (+1.22), REGN: 592.40 (+11.46)
Amgen (AMGN) Stock Higher as Barclays Increases Price Target
at The Street - Fri Jul 31, 2:31PM CDT
Amgen (AMGN) price target was raised to $185 from $180 at Barclays, which maintained its 'equal weight' rating.
AMGN: 176.44 (+1.64)
Stocks Are Mixed as Crude Oil Closes Worst Month of 2015
at The Street - Fri Jul 31, 1:48PM CDT
Stocks are mixed by mid-afternoon Friday as crude oil prices fall and energy stocks sell off.
RCL: 89.95 (+0.80), LNKD: 192.70 (-2.06), EA: 75.16 (+3.36), XOM: 77.17 (unch), AMGN: 176.44 (+1.64), CVX: 84.03 (-1.18), CCE: 51.84 (+1.32)
Amgen Crushes Wall Street's Expectations in Q2, But This Figure Is a Bit Worrisome
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 31, 1:41PM CDT
Source: Amgen via Flickr. The original biotech blue-chip stock, Amgen , continued its recent string of earnings beats when it reported its second-quarter earnings results after the closing bell last night. Amgen's Q2, by the numbers For the...
AMGN: 176.44 (+1.64)
Stocks Are Slightly Higher Despite Energy Drag
at The Street - Fri Jul 31, 10:28AM CDT
Markets move slightly higher Friday shaking off earlier pressure from the energy sector
RCL: 89.95 (+0.80), LNKD: 192.70 (-2.06), EA: 75.16 (+3.36), XOM: 77.17 (unch), AMGN: 176.44 (+1.64), CVX: 84.03 (-1.18), CCE: 51.84 (+1.32)
Small-Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Fri Jul 31, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szb6j5/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celator Pharmaceuticals, Inc. - CellAct Pharma GmbH - Cerulean Pharma, Inc. - Cornerstone Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - CytRx Corporation - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - ImmunoCellular Therapeutics, Ltd. - Immunomedics, Inc. - Inbiopro Solutions Pvt. Ltd For more information visit http://www.researchandmarkets.com/research/sz...lcell_lung
IMMU: 2.06 (-0.01), CERU: 3.95 (-0.12), AMGN: 176.44 (+1.64), LLY: 84.73 (+0.68), BIND: 4.58 (-0.13), GSK: 44.17 (+0.72), BMY: 65.06 (+0.22), IMUC: 0.46 (-0.01), AZN: 34.54 (+0.20), CYTR: 2.62 (-0.04), AVEO: 1.41 (-0.03), ABBV: 70.30 (+0.35), EXEL: 6.28 (-0.34), ARRY: 6.10 (+0.29)
Stocks Open Mixed, Dow Lags; Expedia, Amgen, NewLink Rising
at Investor's Business Daily - Fri Jul 31, 9:37AM CDT
Stocks fought in tightly mixed action early Friday, with earnings news and economic data powering a large share of the action. The Nasdaq improved 0.2% and the S&P 500 rose 0.1%, while the Dow Jones industrial average struggled with a 0.1% decline....
MRK: 59.10 (+0.40), UHS: 143.96 (-2.28), PFE: 35.82 (-0.29), NLNK: 51.74 (-0.09), EXPE: 126.79 (+2.23), AMGN: 176.44 (+1.64), XOM: 77.17 (unch), CVX: 84.03 (-1.18), OUTR: 68.71 (-0.85)
